Key Investor Signals
Entered randomized clinical evaluation for type 1 diabetes
The glUCModel study began in July 2025, with Bioinspired Intelligence as a collaborator. It targets 34 adults using insulin injections and evaluates glucose control and app usability.
Co-invented glucose-forecasting patent technology
All three founders are named on US20250107729A1, a published application for glucose prediction and alerts assigned to Complutense and Extremadura universities.
Built on eight funded diabetes-research projects
glUCModel originated in eight competitive national and regional research projects with nearly €1M in combined funding, supporting the technology before company formation.
Team
José Ignacio Hidalgo
Founder
- Led computer-architecture and evolutionary-computation research at Complutense University of Madrid as a full professor.
- Led a 2019–2021 publicly funded project on adaptive glucose control using smart sensors and accessories.
- Co-invented a 2013 university patent on modeling blood glucose through genetic programming, predating the company.
Oscar Garnica
Co-founder
- Worked on application-specific chip design at Lucent Technologies Bell Labs Innovations before his university career.
- Held an associate-professor appointment at Complutense University of Madrid from 2007, researching computer engineering.
- Developed low-power AI hardware and personalized glucose-prediction models in university collaborations with Spanish hospitals.
José Manuel Velasco
Co-founder
- Taught and researched at Complutense University of Madrid from 2000, building a long academic background in computing.
- Earned a doctorate in computer engineering with a Cum Laude distinction in 2010, following training in physics and communications.
- Co-authored 2022 research on mood, stress and glucose variability in people with type 1 diabetes using glucose sensors.
Product
glUCModel uses AI-based glucose models in a mobile application that combines glucose forecasts, configurable warnings and insulin-dose recommendations. In its clinical study, continuous glucose monitoring data are used to build personalized models while participants continue their usual insulin injections.
Personalized glucose forecasts
General and personalized models forecast glucose changes up to two hours ahead. The clinical-study workflow uses an initial period of continuous glucose monitoring to develop individual predictions for the intervention group.
Configurable early warnings
The application provides predictive alerts for glucose levels that may become too low or too high. Users can adjust warning settings and view forecasts to support discussions and decisions about their diabetes care.
Insulin decision support
glUCModel combines dose recommendations with glucose information to support people using multiple daily injections. The clinical trial evaluates the app alongside usual care and measures time in target glucose range, usability and treatment satisfaction.
Market Overview
Digital diabetes management combines connected monitoring devices, insulin-delivery systems, software and care services. Software turns glucose data into information for patients and diabetes teams. Health systems, insurers, device manufacturers and individuals purchase different parts of this connected-care ecosystem.
Device purchases currently dominate category spending, but software supports recurring services, data interpretation and clinical workflows. App developers compete through interoperability, usable recommendations and evidence that informs payer and provider decisions. The figures below describe this broader connected-care category.
Global digital diabetes-management revenue, including devices and services, was estimated at $20.2B in 2025.
Device hardware accounted for an estimated 91.5% of global digital diabetes-management revenue in 2025.
Digital diabetes-management software and app revenue is forecast to grow 19.0% annually from 2026 to 2035.
Type 1 diabetes represented an estimated 41.4% of global digital diabetes-management revenue in 2025.
Comparable Outcomes
mySugr
mySugr combined diabetes logging, therapy management, coaching and connected-device data in an app-based service for people with diabetes. Roche acquired all shares in June 2017 when mySugr had over one million users.
Livongo Health
Combined connected devices, personalized guidance, and coaching to help people manage diabetes and other chronic conditions. Teladoc completed the stock-and-cash acquisition in October 2020. The $18.5B headline value was based on Teladoc’s share price when the deal was announced.
Interested in More Startups Like Bioinspired Intelligence?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.